Corrigendum to “Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis.”
Year: 2022
Type: erratum
Abstract: The authors wish to add the following information to their Research Paper: In the original published version of this article, one of the affiliations for Prof. G. Santulli was incomplete; the correct affiliation is: Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Institute for Neuroimmunology and Inflammation, Albert Einstein College of Medicine, New York, NY, USA. Moreover, a declaration concerning the competing interest of one of the authors was not included. This issue has now been rectified; the corrected Declaration of Competing Interest can be found below. Prof. B. Trimarco reports personal fees for speaker bureau, outside the content of the current manuscript, from Malesci, Damor, MSD, and Fidia. The authors would like to apologise for any inconvenience caused. Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysisIn this interim analysis, adding oral L-arginine to standard therapy in patients with severe COVID-19 significantly decreases the length of hospitalization and reduces the respiratory support at 10 but not at 20 days after starting the treatment. Full-Text PDF Open Access
Source: EClinicalMedicine
Authors: Giuseppe Fiorentino, Antonietta Coppola, Raffaele Izzo, Anna Annunziata, Mariano Bernardo, Angela Lombardi, Valentina Trimarco, Gaetano Santulli, Bruno Trimarco
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,500
OpenAlex ID: W4295884614